Progress in Pediatric Cardiology
Volume 25, Issue 1 , Pages 69-78 , April 2008

Pediatric cardiomyopathies related to fatty acid metabolism

  • Kevin D. Hill

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA
    • ,
  • Rizwan Hamid

      Affiliations

    • Medical Genetics, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA
    • ,
  • Vernat J. Exil

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA
    • Corresponding Author InformationCorresponding author. Vanderbilt Children's Hospital, Division of Pediatric Cardiology, Vanderbilt Heart-Center for Inherited Heart Disease, 2200 Children’s Way, 5230 DOT. Nashville, TN 37232-9119 USA. Tel.: +1 615 322 7447; fax: +1 615 322 2210.

References 

  1. Bonnet D, Martin D, Pascale De L, et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation. 1999;100(22):2248–2253
  2. Harpey JP, Charpentier C, Coude M, Divry P, Paturneau-Jouas M. Sudden infant death syndrome and multiple acyl-coenzyme A dehydrogenase deficiency, ethylmalonic–adipic aciduria, or systemic carnitine deficiency. J Pediatr. 1987;110(6):881–884
  3. Saudubray JM, Martin D, de Lonlay P, et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis. 1999;22(4):488–502
  4. Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annu Rev Physiol. 2002;64:477–502
  5. Vockley J, Singh RH, Whiteman DA. Diagnosis and management of defects of mitochondrial beta-oxidation. Curr Opin Clin Nutr Metab Care. 2002;5(6):601–609
  6. Vockley J, Whiteman DA. Defects of mitochondrial beta-oxidation: a growing group of disorders. Neuromuscul Disord. 2002;12(3):235–246
  7. Gregersen N, Andresen BS, Corydon MJ, et al. Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype–phenotype relationship. Human Mutat. 2001;18(3):169–189
  8. Engel AG, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science. 1973;179(76):899–902
  9. DiMauro S, DiMauro PM. Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science. 1973;182(115):929–931
  10. Bennett MJ, Rinaldo P, Strauss AW. Inborn errors of mitochondrial fatty acid oxidation. Crit Rev Clin Lab Sci. 2000;37(1):1–44
  11. Gargiulo CE, Stuhlsatz-Krouper SM, Schaffer JE. Localization of adipocyte long-chain fatty acyl-CoA synthetase at the plasma membrane. J Lipid Res. 1999;40(5):881–892
  12. Marin-Garcia J, Goldenthal MJ. Understanding the impact of mitochondrial defects in cardiovascular disease: a review. J Card Fail. 2002;8(5):347–361
  13. Harpey JP, Charpentier C, Paturneau-Jouas M. Sudden infant death syndrome and inherited disorders of fatty acid beta-oxidation. Biol Neonate. 1990;58(Suppl 1):70–80
  14. Hasegawa T, Hori N, Du W. A case of impairment of mitochondrial fatty acid beta-oxidation. Keio J Med. 2002;51(2):100–106
  15. Rocchiccioli F, Wanders RJ, Aubourg P, et al. Deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase: a cause of lethal myopathy and cardiomyopathy in early childhood. Pediatr Res. 1990;28(6):657–662
  16. Bennett MJ, Allison F, Pollitt RJ, Variend S. Fatty acid oxidation defects as causes of unexpected death in infancy. Prog Clin Biol Res. 1990;321:349–364
  17. Kelly DP, Strauss AW. Inherited cardiomyopathies. N Engl J Med. 1994;330(13):913–919
  18. Strauss AW, Powell CK, Hale DE, et al. Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci U S A. 1995;92(23):10496–10500
  19. Tein I, Vajsar J, MacMillan L, Sherwood WG. Long-chain l-3-hydroxyacyl-coenzyme A dehydrogenase deficiency neuropathy: response to cod liver oil. Neurology. 1999;52(3):640–643
  20. Spiekerkoetter U, Sun B, Khuchua Z, Bennett MJ, Strauss AW. Molecular and phenotypic heterogeneity in mitochondrial trifunctional protein deficiency due to beta-subunit mutations. Human Mutat. 2003;21(6):598–607
  21. Stanley CA, Treem WR, Hale DE, Coates PM. A genetic defect in carnitine transport causing primary carnitine deficiency. Prog Clin Biol Res. 1990;321:457–464
  22. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. Jama. 2006;296(15):1867–1876
  23. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348(17):1647–1655
  24. Brackett JC, Sims HF, Rinaldo P, et al. Two alpha subunit donor splice site mutations cause human trifunctional protein deficiency. J Clin Invest. 1995;95(5):2076–2082
  25. Grunewald S, Bakkeren J, Wanders RA, Wendel U. Neonatal lethal mitochondrial trifunctional protein deficiency mimicking a respiratory chain defect. J Inherit Metab Dis. 1997;20(6):835–836
  26. Knabb MT, Saffitz JE, Corr PB, Sobel BE. The dependence of electrophysiological derangements on accumulation of endogenous long-chain acyl carnitine in hypoxic neonatal rat myocytes. Circ Res. 1986;58(2):230–240
  27. Corr PB, Creer MH, Yamada KA, Saffitz JE, Sobel BE. Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest. 1989;83(3):927–936
  28. Exil VJ, Roberts RL, Sims H, et al. Very-long-chain acyl-coenzyme a dehydrogenase deficiency in mice. Circ Res. 2003;93(5):448–455
  29. Werdich AA, Baudenbacher F, Dzhura I, et al. Polymorphic ventricular tachycardia and abnormal Ca2+ handling in very-long-chain acyl-CoA dehydrogenase null mice. Am J Physiol. 2007;292(5):H2202–H2211
  30. Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006;142(2):77–85
  31. Winter S, Jue K, Prochazka J, et al. The role of l-carnitine in pediatric cardiomyopathy. J Child Neurol. 1995;10(Suppl 2):S45–S51
  32. Scaglia F, Scheuerle AE, Towbin JA, Armstrong DL, Sweetman L, Wong LJ. Neonatal presentation of ventricular tachycardia and a Reye-like syndrome episode associated with disturbed mitochondrial energy metabolism. BMC Pediatr. 2002;2:12
  33. Iacobazzi V, Pasquali M, Singh R, et al. Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. Am J Med Genet A. 2004;126(2):150–155
  34. Sharma R, Perszyk AA, Marangi D, Monteiro C, Raja S. Lethal neonatal carnitine palmitoyltransferase II deficiency: an unusual presentation of a rare disorder. Am J Perinatol. 2003;20(1):25–32
  35. Hug G, Bove KE, Soukup S. Lethal neonatal multiorgan deficiency of carnitine palmitoyltransferase II. N Engl J Med. 1991;325(26):1862–1864
  36. Demaugre F, Bonnefont JP, Colonna M, Cepanec C, Leroux JP, Saudubray JM. Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies. J Clin Invest. 1991;87(3):859–864
  37. Egidio RJ, Francis GL, Coates PM, Hale DE, Roesel A. Medium-chain acyl-CoA dehydrogenase deficiency. Am Fam Phys. 1989;39(5):221–226
  38. Touma EH, Charpentier C. Medium chain acyl-CoA dehydrogenase deficiency. Arch Dis Child. 1992;67(1):142–145
  39. Hegyi T, Ostfeld B, Gardner K. Medium chain acyl-coenzyme A dehydrogenase deficiency and SIDS. N J Med. 1992;89(5):385–392
  40. Kemp PM, Little BB, Bost RO, Dawson DB. Whole blood levels of dodecanoic acid, a routinely detectable forensic marker for a genetic disease often misdiagnosed as sudden infant death syndrome (SIDS): MCAD deficiency. Am J Forensic Med Pathol. 1996;17(1):79–82
  41. Bennett MJ, Rinaldo P, Millington DS, Tanaka K, Yokota I, Coates PM. Medium-chain acyl-CoA dehydrogenase deficiency: postmortem diagnosis in a case of sudden infant death and neonatal diagnosis of an affected sibling. Pediatr Pathol. 1991;11(6):889–895
  42. Feillet F, Steinmann G, Vianey-Saban C, et al. Adult presentation of MCAD deficiency revealed by coma and severe arrythmias. Intensive Care Med. 2003;29(9):1594–1597
  43. Sanatani S, Mahkseed N, Vallance H, Brugada R. The Brugada ECG pattern in a neonate. J Cardiovasc Electrophysiol. 2005;16(3):342–344
  44. Gregersen N, Winter V, Jensen PK, et al. Prenatal diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in a family with a previous fatal case of sudden unexpected death in childhood. Prenat Diagn. 1995;15(1):82–86
  45. Nada MA, Vianey-Saban C, Roe CR, et al. Prenatal diagnosis of mitochondrial fatty acid oxidation defects. Prenat Diagn. 1996;16(2):117–124
  46. Andresen BS, Olpin S, Poorthuis BJ, et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet. 1999;64(2):479–494
  47. Mathur A, Sims HF, Gopalakrishnan D, et al. Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. Circulation. 1999;99(10):1337–1343
  48. Pons R, Cavadini P, Baratta S, et al. Clinical and molecular heterogeneity in very-long-chain acyl-coenzyme A dehydrogenase deficiency. Pediatr Neurol. 2000;22(2):98–105
  49. Brown-Harrison MC, Nada MA, Sprecher H, et al. Very long chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. Biochem Mol Med. 1996;58(1):59–65
  50. Vianey-Saban C, Divry P, Brivet M, et al. Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta. 1998;269(1):43–62
  51. Touma EH, Rashed MS, Vianey-Saban C, et al. A severe genotype with favourable outcome in very long chain acyl-CoA dehydrogenase deficiency. Arch Dis Child. 2001;84(1):58–60
  52. Matern D, Strauss AW, Hillman SL, Mayatepek E, Millington DS, Trefz FK. Diagnosis of mitochondrial trifunctional protein deficiency in a blood spot from the newborn screening card by tandem mass spectrometry and DNA analysis. Pediatr Res. 1999;46(1):45–49
  53. Hintz SR, Matern D, Strauss A, et al. Early neonatal diagnosis of long-chain 3-hydroxyacyl coenzyme a dehydrogenase and mitochondrial trifunctional protein deficiencies. Mol Genet Metab. 2002;75(2):120–127
  54. Sims HF, Brackett JC, Powell CK, et al. The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci U S A. 1995;92(3):841–845
  55. Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med. 1999;340(22):1723–1731
  56. Goodman SI, Frerman FE. Glutaric acidaemia type II (multiple acyl-CoA dehydrogenation deficiency). J Inherit Metab Dis. 1984;7(Suppl 1):33–37
  57. Frerman FE, Goodman SI. Deficiency of electron transfer flavoprotein or electron transfer flavoprotein:ubiquinone oxidoreductase in glutaric acidemia type II fibroblasts. Proc Natl Acad Sci U S A. 1985;82(13):4517–4520
  58. Purevjav E, Kimura M, Takusa Y, et al. Molecular study of electron transfer flavoprotein alpha-subunit deficiency in two Japanese children with different phenotypes of glutaric acidemia type II. Eur J Clin Invest. 2002;32(9):707–712
  59. Yamaguchi S, Orii T, Suzuki Y, Maeda K, Oshima M, Hashimoto T. Newly identified forms of electron transfer flavoprotein deficiency in two patients with glutaric aciduria type II. Pediatr Res. 1991;29(1):60–63
  60. Gregersen N. The acyl-CoA dehydrogenation deficiencies. Recent advances in the enzymic characterization and understanding of the metabolic and pathophysiological disturbances in patients with acyl-CoA dehydrogenation deficiencies. Scand J Clin Lab Invest Suppl. 1985;174:1–60
  61. Gregersen N. Riboflavin-responsive defects of beta-oxidation. J Inherit Metab Dis. 1985;8(Suppl 1):65–69
  62. Amendt BA, Rhead WJ. The multiple acyl-coenzyme A dehydrogenation disorders, glutaric aciduria type II and ethylmalonic–adipic aciduria. Mitochondrial fatty acid oxidation, acyl-coenzyme A dehydrogenase, and electron transfer flavoprotein activities in fibroblasts. J Clin Invest. 1986;78(1):205–213
  63. Di Donato S, Frerman FE, Rimoldi M, Rinaldo P, Taroni F, Wiesmann UN. Systemic carnitine deficiency due to lack of electron transfer flavoprotein:ubiquinone oxidoreductase. Neurology. 1986;36(7):957–963
  64. Mandel H, Africk D, Blitzer M, Shapira E. The importance of recognizing secondary carnitine deficiency in organic acidaemias: case report in glutaric acidaemia type II. J Inherit Metab Dis. 1988;11(4):397–402
  65. Angelini C. Defects of fatty-acid oxidation in muscle. Bailliere's Clin Endocrinol Metab. 1990;4(3):561–582
  66. Slukvin II, Salamat MS, Chandra S. Morphologic studies of the placenta and autopsy findings in neonatal-onset glutaric acidemia type II. Pediatr Dev Pathol. 2002;5(3):315–321
  67. Bell RB, Brownell AK, Roe CR, et al. Electron transfer flavoprotein: ubiquinone oxidoreductase (ETF:QO) deficiency in an adult. Neurology. 1990;40(11):1779–1782
  68. Curcoy A, Olsen RK, Ribes A, et al. Late-onset form of beta-electron transfer flavoprotein deficiency. Mol Genet Metab. 2003;78(4):247–249
  69. Abramovich CM, Prayson RA, McMahon JT, Cohen BH. Ultrastructural examination of the axillary skin biopsy in the diagnosis of metabolic diseases. Human Pathol. 2001;32(6):649–655
  70. Whitman GJ, Chance B, Bode H, et al. Diagnosis and therapeutic evaluation of a pediatric case of cardiomyopathy using phosphorus-31 nuclear magnetic resonance spectroscopy. J Am Coll Cardiol. 1985;5(3):745–749
  71. National Newborn Screening and Genetics Resource Center; Accessed 08/22/2007, at www.marchofdimes.com/peristats.
  72. Frazier DM, Millington DS, McCandless SE, et al. The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005. J Inherit Metab Dis. 2006;29(1):76–85
  73. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003;348(23):2304–2312
  74. Solis JO, Singh RH. Management of fatty acid oxidation disorders: a survey of current treatment strategies. J Am Diet Assoc. 2002;102(12):1800–1803
  75. Frazier EA, Faulkner SC, Seib PM, Harrell JE, Van Devanter SH, Fasules JW. Prolonged extracorporeal life support for bridging to transplant: technical and mechanical considerations. Perfusion. 1997;12(2):93–98
  76. del Nido PJ, Armitage JM, Fricker FJ, et al. Extracorporeal membrane oxygenation support as a bridge to pediatric heart transplantation. Circulation. 1994;90(5 Pt 2):II66–II69
  77. BarZiv SM, McCrindle BW, West LJ, et al. Outcomes of pediatric patients bridged to heart transplantation from extracorporeal membrane oxygenation support. Asaio J. 2007;53(1):97–102

PII: S1058-9813(07)00169-5

doi: 10.1016/j.ppedcard.2007.11.007

Progress in Pediatric Cardiology
Volume 25, Issue 1 , Pages 69-78 , April 2008

Article Tools

* Image Usage & Resolution